AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29578820 — intervention group
Group type: EXPERIMENTAL
Intervention: MSHC without ACP to BSaMA
Number of subjects: 39
Study 29578820 — intervention group
Group type: EXPERIMENTAL
Intervention: MSHC with ACP to the stationary arm
Number of subjects: 39
Study 29578820 — intervention group
Group type: EXPERIMENTAL
Intervention: MSHC with ACP to BSaMA
Number of subjects: 39
Study 30283022 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized isotonic exercise
Number of subjects: 0
Study 30283022 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 30283022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo
Number of subjects: 0
Study 27275651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose followed by 90 mg maintenance dose twice daily)
Number of subjects: 70
Study 27275651 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel (60 mg loading dose followed by 10 mg maintenance dose once daily)
Number of subjects: 70
Study 27275651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor vs. Prasugrel
Number of subjects: 70
Study 25102717 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized injection technique (CIT)
Number of subjects: 28
Study 25102717 — intervention group
Group type: COMPARATOR
Intervention: Conventional infiltration technique with traditional syringe
Number of subjects: 28
Study 22340861 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar plate
Number of subjects: 42
Study 22340861 — intervention group
Group type: COMPARATOR
Intervention: Dorsal Pi-plate
Number of subjects: 42
Study 22340861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 19816918 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-supervised pelvic floor muscle training program (1 pre-operative and 7 post-operative sessions over 12 months)
Number of subjects: 51
Study 19816918 — intervention group
Group type: COMPARATOR
Intervention: Usual care (as provided by the surgeon and hospital staff)
Number of subjects: 51
Study 17262041 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous central venous line (PCVL)
Number of subjects: 96
Study 17262041 — intervention group
Group type: COMPARATOR
Intervention: Peripheral intravenous catheter (PIV)
Number of subjects: 96
Study 15226470 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micro g DFE/d
Number of subjects: 42
Study 15226470 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micro g DFE/d
Number of subjects: 42
Study 15226470 — intervention group
Group type: COMPARATOR
Intervention: 135 micro g DFE/d (low-folate diet)
Number of subjects: 42
Study 12203757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir prophylaxis
Number of subjects: 0
Study 12203757 — intervention group
Group type: COMPARATOR
Intervention: Alternative therapies
Number of subjects: 0
Study 9798418 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention including nurse visits providing parenting information
Number of subjects: 20
Study 7708189 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomeric (iohexol 300 mg I/ml)
Number of subjects: 76
Study 7708189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeric (iodixanol 270 mg I/ml)
Number of subjects: 76
Study 2494947 — intervention group
Group type: EXPERIMENTAL
Intervention: ACF alone (Adriamycin, Cyclophosphamide, Ftorafur)
Number of subjects: 47
Study 2494947 — intervention group
Group type: COMPARATOR
Intervention: ACF/MVMF (Mitomycin C, Vincristine, Methotrexate, Ftorafur)
Number of subjects: 47
Study 326337 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine followed by pyrimethamine-sulfadoxine (Fansidar)
Number of subjects: 74
Study 326337 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine followed by mefloquine
Number of subjects: 74
Study 30616482 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 58
Study 30616482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rTMS)
Number of subjects: 58
Study 27363313 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Tetrahydropalmatine (30 mg twice a day orally)
Number of subjects: 24
Study 27363313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26653717 — intervention group
Group type: EXPERIMENTAL
Intervention: SenSura Mio Convex Soft
Number of subjects: 38
Study 26653717 — intervention group
Group type: COMPARATOR
Intervention: Flat stoma appliance
Number of subjects: 38
Study 23392129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg fluoride milk
Number of subjects: 45
Study 23392129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg fluoride milk
Number of subjects: 45
Study 23392129 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride milk (control group)
Number of subjects: 45
Study 21704236 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 16279
Study 21704236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16279
Study 18418361 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (40 mg)
Number of subjects: 60
Study 18418361 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg)
Number of subjects: 60
Study 18418361 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 60
Study 18418361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16966223 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 45
Study 16966223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14723628 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.0 MIU IFNA
Number of subjects: 68
Study 14723628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 11168867 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-daily ceftriaxone plus amikacin
Number of subjects: 128
Study 11168867 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily ceftazidime plus amikacin
Number of subjects: 128
Study 9314382 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (visualization of the tract before THBDC placement)
Number of subjects: 55
Study 9314382 — intervention group
Group type: COMPARATOR
Intervention: Control group (blind needle passage without contrast material opacification)
Number of subjects: 55
Study 9314382 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental technique applied to additional 35 patients
Number of subjects: 55
Study 8222499 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Ro 42-5892
Number of subjects: 49
Study 8222499 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Ro 42-5892
Number of subjects: 49
Study 8222499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8222499 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Ro 42-5892 (IV)
Number of subjects: 49
Study 8222499 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Ro 42-5892 (IV)
Number of subjects: 49
Study 2880447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temazepam 20 mg
Number of subjects: 0
Study 2880447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29729676 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional ABM program
Number of subjects: 0
Study 29729676 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive ABM program
Number of subjects: 0
Study 29729676 — intervention group
Group type: COMPARATOR
Intervention: ABM (both traditional and adaptive)
Number of subjects: 0
Study 29521247 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice a day for 12 weeks
Number of subjects: 51
Study 29521247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27498244 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change intervention involving Madrassa teachers trained in interactive and participatory teaching methods
Number of subjects: 5926
Study 27498244 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change intervention involving Madrassa teachers
Number of subjects: 5926
Study 24500028 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy living intervention
Number of subjects: 105
Study 24500028 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 105
Study 22301208 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered group (Group C) - actively warmed using cotton blankets and a warm forced-air blanket set at 43°C
Number of subjects: 50
Study 22301208 — intervention group
Group type: COMPARATOR
Intervention: Uncovered group (Group U) - remained uncovered during the induction of general anesthesia
Number of subjects: 50
Study 20066450 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (INF) 5 mg/Kg every 6-8 weeks
Number of subjects: 100
Study 20066450 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg weekly
Number of subjects: 100
Study 20066450 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg every other week
Number of subjects: 100
Study 18679412 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg Diet (ED)
Number of subjects: 152
Study 18679412 — intervention group
Group type: COMPARATOR
Intervention: Bagel Diet (BD)
Number of subjects: 152
Study 18679412 — intervention group
Group type: COMPARATOR
Intervention: Egg (E)
Number of subjects: 152
Study 18679412 — intervention group
Group type: COMPARATOR
Intervention: Bagel (B)
Number of subjects: 152
Study 15591466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (125 mug, twice daily for 6 months)
Number of subjects: 26
Study 15591466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 6 months)
Number of subjects: 26
Study 12883106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 41
Study 12883106 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 41
Study 10710018 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety City program
Number of subjects: 181
Study 10710018 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 181
Study 9344193 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected nevi (40 nevi)
Number of subjects: 13
Study 9344193 — intervention group
Group type: COMPARATOR
Intervention: Protected nevi (40 nevi)
Number of subjects: 13
Study 8154129 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic galvanization
Number of subjects: 110
Study 2948441 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HD-MPA (900 mg daily)
Number of subjects: 90
Study 2948441 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular HD-MPA (1 g IM daily for 5 days, then 1 g twice weekly)
Number of subjects: 90
Study 2948441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and IM HD-MPA
Number of subjects: 90
Study 31563980 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent demandingness
Number of subjects: 6391
Study 31563980 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent responsiveness
Number of subjects: 6391
Study 31563980 — intervention group
Group type: COMPARATOR
Intervention: #Tamojunto intervention
Number of subjects: 6391
Study 29644906 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated saline nasal irrigation
Number of subjects: 23
Study 29644906 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature saline nasal irrigation
Number of subjects: 23
Study 29644906 — intervention group
Group type: COMPARATOR
Intervention: Postheated saline irrigation
Number of subjects: 23
Study 29644906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal patency
Number of subjects: 23
Study 29644906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 23
Study 27509571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum for 15 minutes each hour during hemodialysis
Number of subjects: 61
Study 27509571 — intervention group
Group type: COMPARATOR
Intervention: Control (no chewing gum)
Number of subjects: 61
Study 24528605 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 342
Study 24528605 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 342
Study 24528605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 24528605 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg (active control)
Number of subjects: 342
Study 22521528 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT guided IMRT
Number of subjects: 58
Study 22521528 — intervention group
Group type: COMPARATOR
Intervention: CT guided IMRT
Number of subjects: 58
Study 20008644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg orally once daily
Number of subjects: 225
Study 18327724 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-theoretic approach for binary surrogate and true endpoints
Number of subjects: 0
Study 18327724 — intervention group
Group type: COMPARATOR
Intervention: Existing methods for binary outcomes
Number of subjects: 0
Study 16635047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.5 mg twice daily
Number of subjects: 16
Study 16635047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide >0.5 mg twice daily
Number of subjects: 16
Study 16635047 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg daily
Number of subjects: 16
Study 16635047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Bumetanide and Trandolapril)
Number of subjects: 16
Study 16635047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 16
Study 16635047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide and Trandolapril
Number of subjects: 16
Study 14710962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional control over perception of a Necker cube; varying observers' intentions and focus of primary processing.
Number of subjects: 0
Study 14710962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional control over perception of a Necker cube; varying the focus of primary processing with a small cube.
Number of subjects: 0
Study 14710962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional control over perception; top-down activation or priming of perceptual representations.
Number of subjects: 0
Study 14710962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional control over perception; limits of intentional control.
Number of subjects: 0
Study 10607943 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin p.o. daily at 2100 h for a full circadian cycle (35-71 days)
Number of subjects: 7
Study 10607943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8868528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg b.w. midazolam
Number of subjects: 40
Study 8868528 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (control)
Number of subjects: 40
Study 29540589 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 2064
Study 29540589 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 2064
Study 29540589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study 27624139 — intervention group
Group type: COMPARATOR
Intervention: CATCH only (Comparison)
Number of subjects: 1369
Study 27624139 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH plus school garden intervention (Learn, Grow, Eat & Go!)
Number of subjects: 1369
Study 27624139 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH plus physical activity intervention (Walk Across Texas)
Number of subjects: 1369
Study 27624139 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH plus LGEG plus WAT (Combined)
Number of subjects: 1369
Study 24719708 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection femoral nerve block (SFNB) with 20cc ropivacaine (10mg/cc)
Number of subjects: 40
Study 24719708 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA) with a combination of 300mg ropivacaine, 30mg ketorolac, and 0.5mg epinephrine diluted to 150cc
Number of subjects: 40
Study 24719708 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 40
Study 24719708 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection femoral nerve block (SFNB)
Number of subjects: 40
Study 23467860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran treatment
Number of subjects: 2944
Study 20090356 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Trocar (DT) entry
Number of subjects: 1000
Study 20090356 — intervention group
Group type: COMPARATOR
Intervention: Veress Needle (VN) entry
Number of subjects: 1000
Study 18027115 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic occlusion (bipolar diathermy in 9 cases, clips in 3 cases)
Number of subjects: 27
Study 18027115 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic occlusion (roller ball electrode)
Number of subjects: 27
Study 18027115 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic tubal occlusion
Number of subjects: 27
Study 18027115 — intervention group
Group type: EXPERIMENTAL
Intervention: Second‐look office hysteroscopy in Group B
Number of subjects: 27
Study 16186436 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 302
Study 16186436 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 302
Study 12373047 — intervention group
Group type: EXPERIMENTAL
Intervention: RA approach (new method for transseptal catheterization)
Number of subjects: 102
Study 12373047 — intervention group
Group type: COMPARATOR
Intervention: LA approach (control method for transseptal catheterization)
Number of subjects: 102
Study 9950438 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) with an autologous tumour cell‐BCG vaccine, three weekly vaccinations starting 4 weeks after surgery, booster vaccination at 6 months with 10(7) irradiated autologous tumour cells and 10(7) BCG organisms in the first vaccinations.
Number of subjects: 254
Study 9950438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment).
Number of subjects: 254
Study 9950438 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) specifically in stage II disease.
Number of subjects: 254
Study 9950438 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) overall.
Number of subjects: 254
Study 8542532 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intense aerobic exercise for 30 to 35 minutes, two times per week
Number of subjects: 50
Study 8542532 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intense aerobic exercise for 30 to 35 minutes, three times per week
Number of subjects: 50
Study 8542532 — intervention group
Group type: COMPARATOR
Intervention: Very light physical activity at home (Control group)
Number of subjects: 50
Study 2275326 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4-5 micrograms.kg-1 p.o. in addition to pethidine 1 mg.kg-1 i.m.
Number of subjects: 20
Study 2275326 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1 mg.kg-1 i.m. (Control Group)
Number of subjects: 20
Study 7267490 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriosonde 1225
Number of subjects: 18
Study 7267490 — intervention group
Group type: COMPARATOR
Intervention: Bosomat 11D
Number of subjects: 18
Study 7267490 — intervention group
Group type: COMPARATOR
Intervention: Elag Koln BE 237R
Number of subjects: 18
Study 7267490 — intervention group
Group type: COMPARATOR
Intervention: Omron HEM 3
Number of subjects: 18
Study 7267490 — intervention group
Group type: COMPARATOR
Intervention: Hawksley Random Zero Sphygmomanometer
Number of subjects: 18
Study 31363925 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Activity Program (HAP) - a culturally adapted behavioral activation treatment
Number of subjects: 0
Study 31363925 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 0
Study 26616243 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 12
Study 26616243 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step mouthwash
Number of subjects: 12
Study 26616243 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 26616243 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 12
Study 25468006 — intervention group
Group type: EXPERIMENTAL
Intervention: No illicit drug use (baseline negative; n = 50)
Number of subjects: 125
Study 25468006 — intervention group
Group type: COMPARATOR
Intervention: Any illicit drug use (baseline positive; n = 75)
Number of subjects: 125
Study 24044764 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM of 33°C
Number of subjects: 950
Study 24044764 — intervention group
Group type: COMPARATOR
Intervention: TTM of 36°C
Number of subjects: 950
Study 21463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 13
Study 21463543 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 13
Study 21463543 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study 19063650 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure intervention for parents considering an exemption
Number of subjects: 0
Study 16732752 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (XR)
Number of subjects: 60
Study 16732752 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 60
Study 15353899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extract Iscador treatment (subcutaneously for at least 3 months)
Number of subjects: 1442
Study 15353899 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (control group)
Number of subjects: 1442
Study 15353899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extract Iscador treatment
Number of subjects: 1442
Study 11398117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg twice daily for 3 days (adults and adolescents)
Number of subjects: 100